PALM INTRANET

Day : Wednesday
Date: 7/28/2004
Time: 07:48:32

Inventor Name Search Result

Your Search was:

Last Name = MILLER
First Name = DUANE

Application#	Patent#	Status	Date Filed	Title	Inventor Name 51
60555803	Not Issued	020	03/24/2004	ANALOGS EXHIBITING INHIBITION OF CELL PROLIFERATION AND THEIR USE IN TREATING DISEASES	MILLER, DUANE D.
60543724	Not Issued	020	02/11/2004	SYNTHETIC PHOSPHOLIPID SKT INHIBITORS FOR CENCER	MILLER, DUANE D.
60543712	Not Issued	020	02/11/2004	CONFORMATIONALLY RESTRICTED SELECTIVE ANDROGEN RECEPTOR MODULATORS	MILLER, DUANE D.
60529573	Not Issued	018	12/16/2003	PRODRUGS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
60523079	Not Issued	020	11/18/2003	THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USE THEREOF	MILLER, DUANE D.
60511071	Not Issued	020	10/15/2003	ANTI-CANCER COMPOUNDS AND METHODS OF USE THEREOF	MILLER, DUANE D.
60510138	Not Issued	020	10/14/2003	TREATING BONE-RELATED DISORDERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS	MILLER, DUANE D.
60509971	Not Issued	020	10/09/2003	LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE	MILLER, DUANE D.
60453736	Not Issued	159	02/28/2002	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
60453704	Not Issued	159	02/28/2002	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND	MILLER, DUANE D.

				METHODS OF USE THEREOF	
60418336	Not Issued	159	10/16/2002	TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS	MILLER, DUANE D.
60418229	Not Issued	159	10/15/2002	TREATING OBESITY WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS	MILLER, DUANE D.
60418192	Not Issued	159	10/15/2002	TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS	MILLER, DUANE D.
60418173	Not Issued	159	10/15/2002	HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
60418166	Not Issued	159	10/15/2002	METHYLENE-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
60367355	Not Issued	159	08/24/2000	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
60363952	Not Issued	159	03/13/2002	SUBSTITUTED TETRAHYDROISOQUINOLINE AND USE THEREOF TO INHIBIT GLIOMA AND/OR GLIOBLASTOMA GROWTH	MILLER, DUANE D.
60354300	Not Issued	159	02/07/2002	TREATING BENIGN PROSTATE HYPERPLASIA WITH SARMS	MILLER, DUANE D.
60336185	Not Issued	159	12/06/2001	TREATING CHRONIC MUSCLE WASTING WITH SARMS	MILLER, DUANE
60311320	Not Issued	159	08/10/2001	NOVEL ALPHA-ADRENERGIC ANTAGONISTS	MILLER, DUANE D.
60300083	Not Issued	159	06/25/2001	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
60285218	Not Issued	159	04/20/2001	COMPOSITIONS CONTAINING LYSOPHOSPHOTIDIC ACIDS WHICH INHIBIT APOPTOSIS, METHODS OF MAKING THE COMPOSITIONS AND USES THEREOF	MILLER, DUANE D.
60278181	Not Issued	159	03/23/2001	YOHIMBINE DIMERS EXHIBITING BINDING SELECTIVITY FOR	MILLER, DUANE D.

				HUMAN ALPHA2A- VERSUS ALPHA2B- ADRENERGIC RECEPTORS	
60265269	Not Issued	159	01/30/2001	INTERNET PRINT GUIDE	MILLER, DUANE
60243748	Not Issued	159	10/30/2000	METHOD AND APPARATUS FOR INDEXING, SEARCHING, DISTRIBUTING, AND MANAGING MULTIMEDIA RESOURCES	MILLER, DUANE
60193168	Not Issued	159	03/29/2000	B3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME	MILLER, DUANE D.
60190370	Not Issued	159	03/17/2000	SYNTHETIC LYSOPHOSPHATIDIC ACID (LPA) RECEPTOR AGONISTS AND ANTAGONISTS AND USES THEREOF	MILLER, DUANE D.
10849039	Not Issued	019	05/20/2004	METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
10809757	Not Issued	030	03/25/2004	REAL-TIME POLYMERASE CHAIN REACTION-BASED GENOTYPING ASSAY FOR SINGLE NUCLEOTIDE POLYMORPHISM	MILLER, DUANE
10800021	Not Issued	019	03/15/2004	METHOD FOR DETECTING SELECTIVE ANDROGEN RECEPTOR MODULATORS	MILLER, DUANE D.
10760152	Not Issued	019	01/20/2004	METHOD OF TREATING BREAST CANCER WITH ANDROGEN RECEPTOR ANTAGONISTS	MILLER, DUANE D.
10759538	Not Issued	019	01/20/2004	TREATING ANDROGEN DEFICIENCY IN FEMALE (ADIF)-ASSOCIATED CONDITIONS WITH SARMS	MILLER, DUANE D.
10754626	Not Issued	019	01/12/2004	LARGE-SCALE SYNTHESIS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS	MILLER, DUANE D.
10684582	Not Issued	019	10/15/2003	HALOACETAMIDE AND AZIDE SUBSTITUTED COMPOUNDS AND METHODS OF USE THEREOF	MILLER, DUANE D.
10683160	Not Issued	019	10/14/2003	TREATING OBESITY WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS	MILLER, DUANE D.

10683157	Not Issued	030	10/14/2003	METHYLENE-BRIDGED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
10683156	Not Issued	020	10/14/2003	METHOD FOR DETECTING SELECTIVE ANDROGEN RECEPTOR MODULATORS	MILLER, DUANE D.
10683125	Not Issued	020	10/14/2003	HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
10679722	Not Issued	030	10/06/2003	YOHIMBINE DIMERS EXHIBITING BINDING SELECTIVITIES FOR ALPHA2 ADRENERGIC RECEPTORS	MILLER, DUANE D.
10270263	Not Issued	160	10/15/2002	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
10269438	6596734	150	10/11/2002	TETRAHYDROISOQUINOLINE COMPOUNDS FOR USE AS BETA3-ADRENORECEPTOR AGONISTS	MILLER, DUANE D.
10215547	Not Issued	041	08/09/2002	NOVEL ALPHA ADRENERGIC AGENTS	MILLER, DUANE D.
10149953	6593341	150	06/17/2002	BETA3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME	MILLER, DUANE D.
09953686	Not Issued	061	09/17/2001	LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE	MILLER, DUANE D.
09935045	6569896	150	08/23/2001	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
09935044	6492554	150	08/23/2001	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
09923253	6710346	150	08/02/2001	ACTIVE INFRARED PRESENCE SENSOR	MILLER, DUANE SCOTT
09811838	Not Issued	120	03/19/2001	LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE	MILLER, DUANE D.
09708090	Not	161	11/08/2000	NON-STEROIDAL AGONIST	MILLER,

10270732	Not Issued	041	10/16/2002	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
10270233	Not Issued	030	10/15/2002	SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF	MILLER, DUANE D.
10270232	Not Issued	071	10/15/2002	FORMULATIONS COMPRISING SELECTIVE ANDROGEN RECEPTOR MODULATORS	MILLER, DUANE D.
10106521	6638943	150	03/25/2002	YOHIMBINE DIMERS EXHIBITING BINDING SELECTIVITIES FOR ALPHA2 ADRENERGIC RECEPTORS	MILLER, DUANE D.
09461543	Not Issued	161	12/15/1999	NON-STEROIDAL RADIOLABELED AGONIST/ANTAGONIST COMPOUNDS AND THEIR USE IN PROSTATE CANCER IMAGING	MILLER , DUANE D.
09090425	6019957	150	06/04/1998	NON-STEROIDAL RADIOLABELED AGONIST/ANTAGONIST COMPOUNDS AND THEIR USE IN PROSTATE CANCER IMAGING	MILLER , DUANE D.
09086699	6160011	150	05/29/1998	NON-STEROIDAL AGONIST COMPOUNDS AND THEIR USE IN MALE HORMONE THERAPY	MILLER , DUANE D.
08998259	5997252	150	12/24/1997	WIND DRIVEN ELECTRICAL POWER GENERATING APPARATUS	MILLER , DUANE G.
08978511	6071957	150	11/25/1997	IRREVERSIBLE NON-STEROIDAL ANTAGONIST COMPOUND AND ITS USE IN THE TREATMENT OF PROSTATE CANCER	MILLER , DUANE D.
08617370	Not Issued	161	03/18/1996	DRUGS FOR THE TREATMENT OF CARDIAC ARREST AND OTHER SHOCK STATES	MILLER , DUANE D.
08312665	5527830	150	09/26/1994	DRUGS FOR THE TREATMENT OF CARDIAC ARREST AND OTHER SHOCK STATES	MILLER , DUANE D.
08214351	Not Issued	161	03/15/1994	AMPA ANTAGONISTS	MILLER , DUANE D.
08119661	Not Issued	166	09/13/1993	DRUGS FOR THE TREATMENT OF CARDIAC ARREST AND OTHER SHOCK STATES	MILLER , DUANE D.
07816643	Not	161	01/02/1992	FOUR WHEEL VEHICLE WITH	MILLER ,

	Issued			COMPOUNDS AND THEIR USE IN MALE HORMONE THERAPY	DUANE D.
09580640	Not Issued	161	05/30/2000	PROTECTOR PLATE	MILLER, DUANE J.
09510108	6482861	150	02/22/2000	IRREVERSIBLE NON-STEROIDAL ANTAGONIST COMPOUND AND ITS USE IN THE TREATMENT OF PROSTATE CANCER	MILLER, DUANE D

Search and Display More Records.

Search Another: Inventor

Last Name Miller **First Name** Duane

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

STN-STRUCTURE SEARCH
7-28-04

=> d ibib abs hitstr 1-6

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:932559 CAPLUS
DOCUMENT NUMBER: 139:17118
TITLE: Yohimbine dimers exhibiting selectivity for the human α2c-adrenoceptor subtype
AUTHOR(S): Lalchandani, Shilpa G.; Lei, Longping; Zheng, Weiping; Suni, Mustafa M.; Moore, Bob M.; Liggett, Stephen B.; Miller, Duane D.; Feller, Dennis R.
CORPORATE SOURCE: Department of Pharmacology, University of Mississippi, University, MS, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2002), 303(3), 979-984
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Yohimbine is a potent and selective α2- vs. α1-adrenoceptor antagonist. To date, drugs with high specificity for the α2-adrenoceptor show marginal selectivity among the three α2-adrenoceptor subtypes. Initial studies showed that yohimbine was about 4- and 15-fold more selective for the human α2C-adrenoceptor in comparison with the α2A- and α2B-adrenoceptors, resp. To improve on this α2-adrenoceptor subtype selectivity, a series of yohimbine dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on human α2-adrenoceptor subtypes expressed in Chinese hamster ovary cells. Each dimeric analog showed higher affinities for α2A- and α2C-adrenoceptor vs. the α2B-adrenoceptor; and yohimbine dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the α2C-adrenoceptor. The yohimbine dimers n = 3 and n = 24 showed the highest potency and selectivity (32- and 82-fold. resp.) for the α2C-adrenoceptor in receptor binding and in functional studies (42- and 29-fold, resp.) measuring cAMP changes using a cell-based luciferase reporter gene assay. The dimers (n = 3 and n = 24) had high selectivity (>1000-fold) for the α2C-adrenoceptor compared with the three α1-adrenoceptor subtypes. These findings demonstrate that the addition of spacer linkages to bivalent yohimbine mols. provides a successful approach to the development of ligands that are potent and highly selective for the α2C-adrenoceptor.

IT **538357-71-0 538357-72-1 538357-73-2**
538357-74-3 538357-75-4 538357-76-5
538357-77-6 538357-78-7 538357-79-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(yohimbine dimers exhibiting selectivity for human α2c-adrenoceptor subtype)

RN 538357-71-0 CAPLUS
CN Yohimban-16-carboxamide, N,N'-1,2-ethanediylbis[17-hydroxy-, (16α,17α)-(16'α,17'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 538357-72-1 CAPLUS
CN Yohimban-16-carboxamide, N,N'-1,3-propanediylbis[17-hydroxy-, (16α,17α)-(16'α,17'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 538357-73-2 CAPLUS
CN Yohimban-16-carboxamide, N,N'-1,4-butanediylbis[17-hydroxy-, (16α,17α)-(16'α,17'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Inventors

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:754163 CAPLUS
DOCUMENT NUMBER: 137:263224
TITLE: Yohimbine dimers exhibiting binding selectivities for α2 adrenergic receptors
INVENTOR(S): Miller, Duane D.; Zheng, Weiping; Moore, Robert M., II; Mustafa, Suni
PATENT ASSIGNEE(S): The University of Tennessee Research Corporation, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076399	A2	20021003	WO 2002-US9267	20020325
WO 2002076399	A3	20021114		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003036547	A1	20030220	US 2002-106521	20020325
US 6638943	B2	20031028		

PRIORITY APPLN. INFO.: US 2001-278181P P 20010323
OTHER SOURCE(S): MARPAT 137:263224
GI



I

AB The yohimbine dimer compds. I (R = linker mol. having a length of 2.5 Å to about 45 Å) were prepared as an α2-AR antagonist and has selectivity of an α2 -AR subtype over another α2-AR subtype. Thus, yohimbinic acid was treated with H2NCH2CH2NH2 to give I (R = CH2CH2).HCl. The binding affinity (Ki) of I (R = CH2CH2).HCl on human α2a-AR was 26.4 ± 7.3 and α2b-AR was 1510 ± 262 with a α2a/α2b selectivity of 57.2.

IT **269745-09-7P 269745-10-0P 269745-11-1P 269745-12-2P 269745-13-3P 269745-14-4P 269745-15-5P 269745-16-6P 269745-17-7P 269745-18-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU



●2 HCl

RN 269745-18-8 CAPLUS
CN Yohimban-16-carboxamide, N,N'-1,12-dodecanediylbis[17-hydroxy-, dihydrochloride, (16α,17α)-(16'α,17'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:235082 CAPLUS
DOCUMENT NUMBER: 132:347779
TITLE: Yohimbine dimers exhibiting binding selectivities for human α2a - versus α2b - adrenergic receptors
AUTHOR(S): Zheng, Weiping; Lei, Longping; Lalchandani, Shilpa; Sun, Guoping; Feller, Dennis R.; Miller, Duane D.

CORPORATE SOURCE: Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN, 38163, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(7), 627-630
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of yohimbine dimers was prepared and evaluated at the human α2a- and α2b-adrenergic receptors (ARs) expressed in Chinese hamster ovary (CHO) cells. All dimers display higher binding selectivities for α2a vs. α2b subtype than yohimbine, and four compds. I (n = 5, 6, 8, 10) represent the most potent and α2a- vs. α2b-AR selective ligands identified so far.

IT **269745-09-7P 269745-10-0P 269745-11-1P 269745-12-2P 269745-13-3P 269745-14-4P 269745-15-5P 269745-16-6P 269745-17-7P 269745-18-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of yohimbine dimers and their binding affinities on human α2a- and α2b-adrenergic receptors)

RN 269745-09-7 CAPLUS
CN Yohimban-16-carboxamide, N,N'-1,2-ethanediylbis[17-hydroxy-, dihydrochloride, (16α,17α)-(16'α,17'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 269745-18-8 CAPLUS
CN Yohimban-16-carboxamide, N,N'-1,12-dodecanediylbis[17-hydroxy-, dihydrochloride, (16α,17α)-(16'α,17'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:736398 CAPLUS
DOCUMENT NUMBER: 132:45085
TITLE: Characterization of a new radioiodinated probe for the α2C adrenoceptor in the mouse brain
AUTHOR(S): Dossin, Olivier; Mouledous, Lionel; Baudry, Xavier;

Tafani, Jean-Andre-Mathieu; Mazarguil, Honore; Zajac, Jean-Marie
CORPORATE SOURCE: Institut de Pharmacologie et de Biologie Structurale, CNRS UPR 9062, Toulouse, 31077, Fr.
SOURCE: Neurochemistry International (1999), Volume Date 2000, 36(1), 7-18
CODEN: NEUIDS; ISSN: 0197-0186
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB [125I]17α-hydroxy-20α-yohimban-16β-(N-4-hydroxyphenethyl)carboxamide or [125I]rauwolscine-OHPC, a new radioiodinated probe derived from rauwolscine was synthesized and its binding characteristics investigated on sections of the mouse caudate putamen. [125I]rauwolscine-OHPC binding was saturable and revealed interaction with a single class of binding sites (KD = 0.171 nM, Bmax = 3082 pCi/mg of tissue). The kinetically derived affinity was in close agreement with the affinity evaluated by saturation expts.: k-1/k+1 (0.0403 min-1/114 106 M-1 min-1) = 0.35 nM. Competition studies revealed interaction with one single class of binding sites for each of the twelve compds. tested. The rank of potency suggested an interaction with α2 adrenoceptors (atipamezole ≥ RX 821002 > yohimbine > (-)epinephrine). Moreover, the good affinity of [125I] rauwolscine-OHPC binding sites for spiroxatrine, yohimbine, WB 4101, the relatively good affinity for prazosin (Ki = 37.4 nM) and the affinity ratio prazosin/oxymetazoline (37.4/43.4=0.86) were consistent with an α2C selective labeling of [125I]rauwolscine-OHPC. The distribution of [125I]rauwolscine-OHPC binding sites in mouse brain was characterized by autoradiog. The d. of binding sites was high in the islands of Calleja, accumbens nucleus, caudate putamen and olfactory tubercles, moderate in the hippocampus, amygdala and anterodorsal nucleus of the thalamus. These findings demonstrated that [125I]rauwolscine-OHPC is a useful radioiodinated probe to label α2C adrenoceptors in mouse brain.
IT **252878-60-7**
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(synthesis and characterization of new radioiodinated probe for α2C adrenoceptor in mouse brain)
RN 252878-60-7 CAPLUS
CN Yohimban-16-carboxamide, 17-hydroxy-N-[2-[4-hydroxy-3-(iodo-125I)phenyl]ethyl]-, (16β,17α,20α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252878-59-4P**
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(synthesis and characterization of new radioiodinated probe for α2C adrenoceptor in mouse brain)

RN 252878-59-4 CAPLUS

CN Yohimban-16-carboxamide, 17-hydroxy-N-[2-(4-hydroxyphenyl)ethyl]-, (16β,17α,20α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:594384 CAPLUS

DOCUMENT NUMBER: 107:194384
TITLE: Purification of the α2-adrenergic receptor from porcine brain using a yohimbine-agarose affinity matrix
AUTHOR(S): Repaske, Mary G.; Nunnari, Jodi M.; Limbird, Lee E.
CORPORATE SOURCE: Dep. Pharmacol., Vanderbilt Univ., Nashville, TN, 37232, USA
SOURCE: Journal of Biological Chemistry (1987), 262(25), 12381-6
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The α2-adrenergic receptors were solubilized from porcine brain particulate prepns. by sequential extraction into Na cholate- and digitonin-containing buffers. The α2-adrenergic receptors in the digitonin extract were identified by using the α2-adrenergic selective antagonist. [3H]yohimbine and demonstrated the same specificity for interaction with adrenergic ligands as did the receptors in particulate prepns. Extraction into digitonin-containing buffers eliminated the modulation of receptor-agonist interactions by guanine nucleotides, but not by monovalent cations. A novel affinity resin, yohimbine-agarose, was synthesized and used for purification of α2-adrenergic receptors. By using 2 sequential yohimbine-agarose affinity chromatog. steps, digitonin-solubilized α2-adrenergic receptors from porcine brain cortex were purified to homogeneity as assessed by radioiodination and Ag stain anal. of these prepns. on SDS-PAGE. The purified α2-adrenergic receptor has an approx. Mr = 65,000, as determined by photolabeling of the adrenergic ligand-binding subunit. The yohimbine-agarose affinity resin should be useful for purifying quantities of receptor sufficient for studies of receptor structure and functions.

IT **111018-62-3P**
RL: PREP (Preparation)
(preparation of, as stationary phase for α2-adrenergic receptor purification by affinity chromatog.)

RN 111018-62-3 CAPLUS
CN Agarose, [3-[[3-[[[(16α,17α)-17-hydroxyyohimban-16-yl]carbonyl]amino]propyl]amino]propyl]carbamimidate (9CI) (CA INDEX NAME)

CM 1

CRN 173761-30-3
CMF C27 H40 N6 O3



CM 2

CRN 9012-36-6

CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1986:403033 CAPLUS
DOCUMENT NUMBER: 105:3033
TITLE: Synthesis and characterization of a high affinity radioiodinated probe for the α2-adrenergic receptor
AUTHOR(S): Lanier, Stephen M.; Hess, Hans Jurgen; Grodski, Alex; Graham, Robert M.; Homcy, Charles J.
CORPORATE SOURCE: Cardiac Unit, Massachusetts Gen. Hosp., Boston, MA, 02114, USA
SOURCE: Molecular Pharmacology (1986), 29(3), 219-27
CODEN: MOPMA3; ISSN: 0026-895X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis and characterization are described of functionalized derivs. of the selective α2-adrenergic antagonists, rauwolscine and yohimbine, which can be radiolabeled to high specific activity with 125I. Following demethylation of rauwolscine or yohimbine, the resultant carboxylic acid derivs. were reacted with 4-aminophenethylamine to yield the resp. 4-aminophenethyl carboxamides, 17α-hydroxy-20α-yohimban-16β-[N-4-amino-phenethyl]carboxamide (rau-pAPC) and 17α-hydroxy-20β-yohimban-16α[N-4-aminophenethyl]carboxamide. In competitive inhibition studies using rat renal membranes and the radioligand [3H]rauwolscine, rau-pAPC (Ki = 11 nM) exhibited a 14-fold greater affinity than the corresponding yohimbine derivative (Ki = 136 nM). The higher affinity compound, rau-pAPC, was radioiodinated by the chloramine T method, and the product, 125I-rau-pAPC [17α-hydroxy-20α-yohimban-16β-(N-4-amino-3-[125i]iodophenethyl)carboxamide], was purified by reversed-phase HPLC to high specific activity (2175 Ci/mmol) and its binding characteristics were investigated in rat kidney membranes. Specific binding of 125I-rau-pAPC was saturable and of high affinity as determined by Scatchard anal. (KD = 1.8 nM) or from kinetic studies (KD = k2/k1 = 0.056 min-1/4.3 ± 0.2 + 107 M-1 min-1 = 1.3 nM). In competition studies, α-adrenergic antagonists and agonists inhibited the binding of 125I-rau-pAPC with a potency order consistent with an interaction at α2-adrenergic receptors (rauwolscine > phentolamine > prazosin; clonidine > (-)-epinephrine > (-)-norepinephrine > dopamine > (+)-epinephrine). In rat liver and human platelet membranes, high affinity binding of 125I-rau-pAPC was also observed (liver, KD = 1.2 nM; platelet, KD = 3.2 nM). In addition, the d. of α2-adrenergic receptors identified from binding studies with 125I-rau-pAPC in kidney, liver, and platelet membranes was similar to that observed in parallel studies with [3H]rauwolscine. These findings indicate that 125I-rau-pAPC is a high affinity probe that selectively identifies α2-adrenergic binding sites. Availability of this radioligand should facilitate the localization and biochem. characterization of this α-adrenergic receptor subtype.

IT **102606-25-7P 102606-26-8P 102679-82-3P**
RL: PREP (Preparation)
(preparation of, as probe for adrenergic receptors)
RN 102606-25-7 CAPLUS
CN Yohimban-16-carboxamide, N-[2-(4-aminophenyl)ethyl]-17-hydroxy-, (16β,17α,20α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102606-26-8 CAPLUS
CN Yohimban-16-carboxamide, N-[2-[4-amino-3-(iodo-125I)phenyl]ethyl]-17-hydroxy-, (16β,17α,20α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102679-82-3 CAPLUS
CN Yohimban-16-carboxamide, N-[2-(4-aminophenyl)ethyl]-17-hydroxy-, (16α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




```
=> d his

     (FILE 'HOME' ENTERED AT 08:06:58 ON 28 JUL 2004)

     FILE 'REGISTRY' ENTERED AT 08:07:04 ON 28 JUL 2004
L1             STRUCTURE UPLOADED
L2               2 S L1
L3              26 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 08:07:38 ON 28 JUL 2004
L4               6 S L3

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

=>